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Abstract 
Ohjective: To assess maternal and perinatal outcomes of expectant management with plasma volume expansion and 
pharmacologic vasodilatation i patients with severe pre-eclampsia remote from term. Study design: All women with severe 
pre-eclampsia between 20 and 32 weeks' gestation, not in labor and with a live, single fetus admitted to the University Hospital 
Rotterdam from 1985 to 1993 were managed with the intention to prolong gestation. Treatment consisted of correction of the 
maternal circulation with vasodilatation by means of dihydralazine and plasma volume expansion under central hemodynamic 
monitoring. Primary end-points of the study were prolongation of gestation, maternal antepartum and postpartum complications, 
and fetal and neonatal outcome. Results: Two-hundred fifty-four patients were included. The median prolongation of pregnancy 
was 14 (range 0 62) days. Hemodynamic treatment was associated with marked objective and subjective improvement in maternal 
condition. Complications of central hemodynamic monitoring were not observed. Perinatal mortality was 20.5%. Conclusion: 
Expectant management with plasma volume expansion and pharmacologic vasodilatation under central hemodynamic monitoring 
of the maternal circulation may delay delivery and enhance fetal maturity and does not appear to be associated with an increased 
risk of maternal morbidity and mortality. 
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1. Introduction 
Pre-eclampsia complicates 5-10% of all pregnancies 
and is directly or indirectly responsible for a large 
proportion of maternal and perinatal mortality and 
morbidity [1]. Although the cause of pre-eclampsia is
still unknown, the placenta is considered a key factor 
[2]. Therefore, delivery of fetus and placenta is the only 
effective treatment, which may benefit he mother but is 
often not in the interest of the second patient, the fetus, 
in particular emote from term. The decision to deliver 
must depend on the estimated balance of maternal and 
fetal-neonatal risks. In preterm pregnancy complicated 
by mild pre-eclampsia the balance of maternal and 
neonatal interests will usually lead to conservative man- 
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agement, in an attempt o postpone delivery in order to 
reduce neonatal morbidity and mortality [1,3]. On the 
other hand, in cases of severe pre-eclampsia or eclamp- 
sia most guidelines recommend expeditious delivery 
regardless of gestational age [1,4], in particular when 
pre-eclampsia s complicated by the HELLP syndrome 
[5,6]. In recent years, as methods for monitoring mater- 
nal and fetal wellbeing improved, these guidelines have 
been challenged and attempts have been made to post- 
pone delivery also in women with severe pre-eclampsia 
remote from term [3,7,8]. However, recent reports of 
small series of patients indicate that such an approach 
could be associated with increased maternal morbidity 
[7]. 
In 1985 a protocol of temporizing management of 
severe pre-eclampsia remote from term was instituted in 
our department. The protocol is based on correction of 
the maternal circulation with plasma volume expansion 
and pharmacologic vasodilatation under central hemo- 
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dynamic monitoring [9]. The purpose of this study is to 
assess the maternal and perinatal outcomes of 254 
consecutive patients with severe pre-eclampsia before 32 
weeks gestation managed according to this protocol. 
2. Patients and methods 
The study population consisted of all women with 
severe pre-eclampsia between 20 and 31 completed 
weeks of gestation, not in labor and with a live, single 
fetus, admitted to the antenatal wards of the University 
Hospital Rotterdam (AZR) between January 1, 1985 
and December 31, 1993. The AZR serves as a perinatal 
tertiary care center for an area with approximately 
35 000 deliveries per year. 
Severe pre-eclampsia was defined as the occurrence 
after 20 weeks" gestation of a diastolic blood pressure, 
before treatment, of >110 mmHg (Korotkoff 4) and 
proteinuria of > 0.3 g/1 in a 24-h urine collection, or 
the occurrence of repetitive diastolic blood pressure 
values of > 90 mmHg and proteinuria in combination 
with the HELLP syndrome or eclampsia. The HELLP 
syndrome was defined as the simultaneous occurrence 
of a platelet count of < 100 x 109/1, serum aspartate 
aminotransferase (ASAT) and serum alanine amino- 
transferase (ALAT) concentrations > 30 U/1 (2 S.D. 
above the mean in our hospital), and hemolysis defined 
by abnormal peripheral blood smear. Patients with 
known vascular, renal, hepatic or hematologic disease 
were excluded. 
Gestational age was based on the last menstrual 
period and confirmed by early ultrasound in the major- 
ity of cases. 
All patients were managed with the intention to 
prolong gestation in order to enhance fetal maturity. 
Temporizing treatment consisted of bed rest and correc- 
tion of the maternal circulation to previously estab- 
lished normal hemodynamic values for the second half 
of gestation [10] by means of pharmacologic vasodilata- 
tion and plasma volume expansion under central hemo- 
dynamic monitoring. Each patient underwent 
pulmonary artery catheterization and radial arterial ine 
placement in the obstetric intensive care unit as previ- 
ously described in detail [9 11]. Briefly, a Swan-Ganz 
catheter was inserted in a median basilic vein and 
advanced into the puhnonary artery under continuous 
oscilloscopic monitoring. Baseline values of systemic 
and pulmonary arterial and venous pressures, and of 
cardiac output, were obtained after a stabilization pe- 
riod of approximately I h. Cardiac output was mea- 
sured in triplicate in supine position at end-expiration 
by means of thermodilution, using 10 ml of chilled 5% 
dextrose solution. Patients with a pulmonary capillary 
wedge pressure (PCWP) of < 10 mmHg received intra- 
venous infusion of pasteurized plasma at a rate of 
approximately 250 ml/h to reach and maintain PCWP 
values of 10 12 mmHg. if, after volume expansion, the 
cardiac index was still <3.5 1.min ~.m z and the 
systemic vascular resistance index was > 2000 
dyne.s.cm ~ -.m-, patients received an intravenous infu- 
sion of dihydralazine at a rate of 1 mg/h followed by 
hourly increments of I mg, until the cardiac index had 
reached a value between 3.5 and 4.6 1.rain l.m e and 
a systemic vascular resistance index of < 2000 
dyne.s.cm 5.m2 had been obtained. When cardiac in- 
dex and systemic vascular resistance had reached nor- 
mal values but diastolic blood pressure was still > 100 
mmHg, antihypertensive treatment with u.-methyldopa 
was added. After a stable hemodynamic condition had 
been obtained and maintained for 1 2 days, the vascu- 
lar catheters were removed and the patient was trans- 
ferred to the antenatal ward. Antihypertensive 
treatment was continued under close monitoring of 
blood pressure, fluid balance, and laboratory values. 
All patients kept bed rest and received an unre- 
stricted diet. Maternal condition was assessed by moni- 
toring blood pressures, fluid balance and pertinent 
laboratory values including protein in 24-h urine sam- 
pies, complete blood counts, liver enzymes (ASAT, 
ALAT, gamma glutamyl transferase, serum lactic dehy- 
drogenase) and total bilirubin, renal function tests 
(serum creatinine and uric acid) and tests for hemolysis 
(peripheral blood smear, serum haptoglobin). Coagula- 
tion tests (activated partial thromboplastin time, 
prothombin time, normotest, thrombotest, fibrinogen, 
fibrinogen degradation products, antithrombin Ill) 
were performed on admission in the majority of pa- 
tients, and during treatment when indicated. Anticon- 
vulsant treatment with intravenous diazepam was used 
in eclamptic patients and when eclampsia ppeared to 
be imminent, as judged by hyperactive deep tendon 
reflexes with clonus. Platelet transfusions were given at 
the time of cesarean section when platelet counts were 
< 30 × 10')/1. Ultrasound examination was performed 
in all patients to detect fetal growth retardation and 
congenital abnormalities. Fetal condition was assessed 
by cardiotocography (non-stress CTG) on admission 
and at least daily thereafter. If labor occurred and 
delivery was still to be postponed, uterine activity was 
inhibited using intravenous fenoterol. Corticosteroids 
to accelerate fetal lung maturation were not used in 
patients with pre-eclampsia during the period of the 
study. 
The decision to deliver was taken by the attending 
obstetrician in consultation with the neonatologist, 
weighing combined maternal and fetal risks against the 
risks of neonatal mortality and morbidity. The mode of 
delivery was individualized and mainly determined by 
fetal condition. Neonates requiring intensive care were 
transferred to our neonatal intensive care unit. Pul- 
monary surfactant herapy was used after 1991. 
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The study protocol was approved by the University 
and Hospital Ethics Committee. The primary end- 
points of the study were the number of days of prolon- 
gation of gestation after admission, predefined maternal 
antepartum and postpartum complications (mortality, 
HELLP syndrome, eclampsia, abruptio placentae, post- 
partum hemorrhage, pulmonary edema), and specified 
measures of fetal and neonatal outcome (birthweight, 
perinatal mortality, neonatal morbidity as judged by 
Apgar score, artifical ventilation, bronchopulmonary 
dysplasia, cerebral bleeding). 
Birthweight is presented as actual weight at birth and 
related to the Dutch reference curve, corrected for 
gestational age, parity and fetal sex [12]. Data on 
perinatal mortality comprise all stillbirths and neonatal 
deaths occurring within 28 days of birth; infant mortal- 
ity includes all deaths between 28 days and 1 year after 
birth. Bronchopulmonary d splasia is defined as a re- 
quirement for oxygen at 28 days of life, irrespective of 
gestational age at birth. 
Data analysis was based on intention to treat and 
included all patients, also when they were delivered 
before the actual start of temporizing treatment. Data 
are presented as median (range) unless stated otherwise. 
Hemodynamic and laboratory values were examined by 
non-parametric one-way analysis of variance for re- 
peated measurements and Wilcoxon's rank sign test as 
appropriate. Categorical variables were assessed with 
the Z-'-test. A P-value of < 0.05 (two-tailed) was 
considered significant. 
3. Results 
During the period of the study 254 patients with 
severe pre-eclampsia before 32 weeks' gestation who 
met the inclusion criteria were delivered at this center. 
General characteristics on admission are summarized in 
Table 1. The majority of the patients (94%) were re- 
ferred from regional hospitals, usually because of com- 
plications such as the HELLP syndrome (33%), 
eclampsia (5%), or severe fetal growth retardation 
Table 1 
General characteristics on admission of 254 patients with severe 
pre-eclampsia 
Age (years) 
Nulliparous 
Geslational age (weeks) 
Diastolic blood pressure (mmHg) 
Antihypertensive treatment 
before admission 
Eclampsia before admission 
HELLP before admission 
Upper abdominal pain 
Severe fetal growth retardation 
27 (18 44) 
188 (74%) 
29.3 (21.7 31.9) 
I10 (90 170) 
138 (54.3%) 
12 (4.7%) 
85 (33.5%) 
116 (45.7%) 
50 (19.7'/,,) 
Values are median (range) or numbers (percentage) as appropriate. 
'Fable 2 
Laboratory data on admission 
Proteinuria (g/I) 2.8 (0.3 35.9) 
~> 5 g/l 80 
Creatinine (jLmol/l) 72 (40 165) 
Uric acid (mmol/l) 0.41 (0.16 0.84) 
Hemoglobin (mmol/1) 7.7 (4.9 10.7) 
Hematocrit (1/I) 0.37 (0.23 0.51) 
Platelets ( x 10'~/I) 145 (14 436) 
50 100 73 
<50 22 
Bilirubin (iLmol/l) 8 (2 75) 
ASAT (UI) 27 (7 779) 
ALAT (U/I) 20 (3 780) 
LDH (U/I) 356 (168 3219) 
Haptoglobin (g/l) 0.2 ( <0.1 2.8) 
Values are median (range) or numbers as appropriate. 
(20%); half the number of patients had already received 
antihypertensive treatment because of a diastolic blood 
pressure of > 110 mmHg. 
Baseline hemodynamic measurements showed pat- 
terns similar to those previously observed in untreated 
and treated pre-eclamptic patients [10] and will be 
reported elsewhere. The total amount of plasma ex- 
pander administered during treatment varied between 1 
and 4 liters, mainly administered during the first 3 days 
after admission. All patients received dihydralazine in 
doses varying between 1 and 15 mg/h; 40% of the 
patients also required :~-methyldopa in doses between 
750 mg and 4 g/24h. The relevant laboratory data on 
admission are shown in Table 2. During treatment 
proteinuria increased significantly (P < 0.001) from a 
median value of 2.8 g/1 to 4.9 g/l, without changes in 
plasma creatinine levels. None of the patients developed 
a creatinine level > 200 izmol/1. Between admission and 
delivery the hemoglobin concentration showed a signifi- 
cant fall from 7.7 to 7.0 mmoH (P < 0.001). 
Table 3 summarizes maternal outcome. There were 
no maternal complications associated with the intro- 
duction or maintenance of the radial artery or Swan- 
Ganz catheter. Pregnancy was terminated within 48 h 
after admission in 13% of patients because of fetal 
distress as judged by the non-stress fetal CTG (n = 29), 
or fetal death (n = 3). When patients delivered within 
48 h are omitted from the calculation, the median 
prolongation of pregnancy was 17 days with a prolon- 
gation of _> 14 days in 51% of the patients. 
Eclampsia occurred in one patient shortly after ad- 
mission, before the start of treatment, followed by 
cortical blindness: normal vision returned 1 day after 
cesarean section for fetal distress. Visual disturbances 
were observed in two other patients. One severely hy- 
pertensive patient developed cortical blindness 1 day 
after the start of treatment; normal vision returned 
within 2 days, and pregnancy was prolonged by 6 days. 
In the second patient temporary visual problems after 
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delivery were due to retinal edema. Bleeding problems 
observed in 6% of patients were not severe and con- 
sisted of abdominal hematoma following cesarean sec- 
tion (n= 12), postpartum uterine bleeding (n= 1), 
hematemesis (n = 1) and a hematoma of the vulva 
(n = 1). Renal failure or disseminated coagulopathy was 
not observed. 
In all patients with the HELLP syndrome the upper 
abdominal pain abated and usually disappeared within 
2 3 h after the start of  treatment. In 42 of 75 patients 
who were admitted with HELLP and who were not 
delivered within 48 h because of fetal distress, all signs 
and symptoms disappeared before delivery. On the 
other hand, 20 women developed a complete antepar- 
tum HELLP syndrome during treatment, which re- 
solved in six patients before delivery. All four patients 
with pulmonary edema were admitted with the HELLP 
syndrome. Two women developed antepartum pul- 
monary edema; the first one during induction of labor 
with prostaglandin E2 after fetal death, the second one 
during tocolysis with fenoterol. Both patients were 
treated successfully with diuretics. In the two patients 
with pulmonary edema after delivery, a diagnosis of 
cardiomyopathy was made by ultrasound; one of these 
patients had received prostaglandin Ee after delivery. 
Both patients needed artificial ventilation for 2 3 days 
and recovered completely. 
Perinatal outcome is shown in Table 4. The high 
Table 4 
Perinatal and neonatal outcome 
Gestational age at delivery (weeks) 31.2 (22.3 37.7) 
Birthweight (g) I 102 (180-2370) 
Belou. 10 'h percentile 149 (58.7%) 
Below 2.3 'd percentile 37 (14.6%) 
Perinatal mortality 52 (20.5%) 
Fetal deaths 3 I 
Gestational age (weeks) 27.1 {22.3 34.4) 
Birthweight (g) 680 (180 23701 
Neonatal deaths 2 I 
Gestational age (weeks} 30.0 (26.6-33.7) 
Birthweight (g) 990 (480 1510) 
Infant deaths 8 
Primary cause of neonatal death 
Respiratory insufficiency 16 
Sepsis 3 
Ruptured cerebral aneurysm 1 
Lelhal congenital abnormality 1 
Neonatal morbidity 
Apgar score at 5 rain < 7 25 
Platelet count < 100 x 10~/I 30 
Cerebral bleeding 
Grade 1-II 8 
Grade 111 2 
Artiticial ventilation 115 
Duration (days) 5 (0.1 61) 
Bronchopulmonary dysplasia 25 
Values are median (range} or numbers (percentage) as appropriate. 
Table 3 
Maternal outcome 
Prolongation of pregnancy (days) 14 (0 62) 
Termination within 48 h 32 (12.6%) 
Prolongation in remaining patients (days) 17 (3 62) 
Antepartum resolution of HELLP 48 (45.7".) 
Prolongation of pregnancy (days) 22 (8 62) 
Maternal mortality 0 
Maternal morbidity 
Eclampsia 1 
Visual disturbances 3 
Abruptio placentae 
Complete I 
Partial 12 
Hemorrhagic problems 15 
HELLP syndrome 
Antepartum 20 
Postpartum 4 
Pulmonary edema 4 
Termination of pregnancy 
Vaginal delivery 43 (16.9%) 
Spontaneous labor 9 
Induced labor 34 
Cesarean section 211 (83.1",) 
Fetal indication 18 I 
Maternal indication 22 
Combined indication 8 
Values arc median (range) or numbers (percentage) as appropriate. 
proportion of very small-for-gestational age (< 2.3 rd 
percentile) infants is mainly caused by the 73 women 
admitted at a gestational age of _< 27 weeks, of whom 
25% were delivered of very small-for-gestational age 
infants compared with 10.5% in women admitted be- 
tween 27 and 32 weeks' gestation (P < 0.01). Total 
perinatal loss was 20.5%, with a 95"/,, confidence inter- 
val of 15 26%. Of the 52 cases of perinatal loss, 60% 
were due to fetal death. All stillbirths, except one 
caused by complete abruptio placentae at 34 weeks" 
gestation, occurred in cases with severe fetal growth 
retardation at gestational ages < 30 weeks. Although 
fetal distress was recognized, it was decided not to 
deliver because of low estimated birthweight, small 
chance of survival, or high estimated risk of serious 
morbidity and later handicap. The majority of neonatal 
deaths (76%) were due to respiratory distress associated 
with very preterm birth. One of the two infants with a 
cerebral bleeding grade Ill had a raptured cerebral 
aneurysma and died I day after birth, the other intimt 
survived and showed a minor delay in speech develop- 
ment at the age of 1 year. No correlation could be 
demonstrated between the last maternal platelet count 
before delivery and neonatal platelet count. Eight in- 
fants died in their first year of life, in all cases due to 
severe bronchopulmonary dysplasia. 
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Table 5 
Perinatal outcome by gestational age on admission 
151 
Gestational age Number Prolongation Birthweight Birthweight percentile Fetal deaths Neonatal Perinatal mortality 
(weeks) (days) (g) (n) deaths 
• < 10 th < 2.3"'* (n) % 95% CI 
(n) 01) 
<26 25 16 (2 42) 650(180 990) 16 9 16 5 84 64 95 
26 18 15 (0 60) 900 (480 1785) 11 3 5 3 44 22 69 
27 30 18 (3 61) 1027 (675 1800) 22 6 5 4 30 15 49 
28 42 12 (0 62) 965 (640 2130) 25 4 1 6 17 7 31 
29 44 13 (0 46) 1115 (625 2140) 27 8 3 1 9 3 22 
30 47 12 (1 50) 1290 (610 1860) 25 2 0 2 4 I 15 
31 48 13 (0 39) 1527 (955 2370) 23 5 1 0 2 1 11 
Values are numbers or medians (ranges} as appropriate. CI, confidence interval. 
Table 5 shows perinatal outcome related to gesta- 
tional age on admission and prolongation of preg- 
nancy. Of the 25 pregnancies with an onset of 
pre-eclampsia before 26 weeks' gestation, only four 
babies survived and did well, after a median prolonga- 
tion of pregnancy of 16 (2 42) days. Perinatal survival 
improved significantly with gestational age, with reduc- 
tions in perinatal mortality of approximately 50% per 
week between 27 and 32 weeks' gestation on admission. 
4. Discussion 
Severe pre-eclampsia < 32 weeks' gestation is an 
infrequent complication of pregnancy and published 
experience in managing such patients is limited. In this 
report we present our experience with temporizing man- 
agement in what is, to the best of our knowledge, the 
largest consecutive series of patients with severe pre- 
eclampsia remote from term treated in one center. Our 
treatment is based on the assumption that symptomatic 
correction of maternal hemodynamics may improve 
perfusion of maternal tissues and organs and could thus 
benefit the mother and perhaps also the fetus [13,14]. 
Whereas hemodynamics in untreated pre-eclamptic 
women are characterized by a reduced cardiac output 
and circulating volume and a high peripheral vascular 
resistance, patients receiving antihypertensive drugs and 
intravenous fluids show hemodynamic patterns that are 
variable and unpredictable [10]. For that reason we 
consider central hemodynamic monitoring an indis- 
pensable tool to assess the hemodynamic balance of 
flow, pressure and resistance in the systemic and in 
particular the pulmonary circulations in treated pre- 
eclamptic patients referred from other hospitals, and to 
monitor antihypertensive treatment and plasma volume 
expansion [13]. Based on the results of the present study 
and on previously reported experience [10,11], the ma- 
ternal risks of the invasive hemodynamic monitoring 
applied in the first 1 3 days of treatment appear to be 
small in our hands. This may, at least in part, be 
attributed to the small number of skilled operators 
involved, and to the presence in the obstetric intensive 
care unit of an experienced medical and nursing staff, 
24 h per day and 7 days per week. 
In contrast o other reports on conservative manage- 
ment in which patients with the HELLP syndrome 
[7,8,15-17], with eclampsia [4,7,8,16 18], with severe 
fetal growth retardation [8,17], and with fetal distress 
[8,15 17] were excluded, our study includes all patients 
with early onset pre-eclampsia nd a live fetus on 
admission. Despite the presence of eclampsia, HELLP, 
and fetal compromise, in more than 40% of cases, the 
mean prolongation of pregnancy of 16 (range 0 62) 
days is similar [4,8,15,17,19] or better [7,16,18,20] than 
that reported in comparable studies in selected patients. 
In contrast to the results of a recent study [7], 
suggesting that expectant management without hemo- 
dynamic correction in patients with severe pre-eclamp- 
sia may increase maternal morbidity, in our study 
hemodynamic treatment was associated with marked 
objective and subjective improvement in maternal con- 
dition. We did not observe maternal mortality [6,18] 
and severe complications uch as ruptured liver he- 
matoma [4,6], intracerebral hemorrhage [4] and renal 
failure [4,6,7,18]. In our study four (1.6%) patients 
developed pulmonary edema, which compares favor- 
ably with the reported incidence of 2.9% among pre- 
eclamptic patients [21]. Two of these patients were 
treated with prostaglandin E> and one with fenoterol, 
drugs that have been reported to cause [22] or exacer- 
bate pulmonary edema [23]. The observation of com- 
plete resolution of the HELLP syndrome before 
delivery in 51% of the patients in whom pregnancy 
could be prolonged for > 48 h, supports our earlier 
report on the beneficial maternal effects of temporizing 
hemodynamic treatment in patients with HELLP [11]. 
Although it is said that the natural history of the 
HELLP syndrome is that of a deteriorating postpartum 
process [24], HELLP recurred post partum in only two 
patients. 
152 D'. Visser, H.C.S. D}dhqlhurg /European Journal ol Ohsletrics & Gvnec'olog.v amt Reproductize Biology 63 (1995) 147 1,54 
Table 6 
Comparison belween maternal and perinatal outcome of temporizing management m patients with severe pre-eclampsia remote from term in the 
University Hospital Rotterdam (AZR) 1985 I993, and as published in the literature 
This study,' Olfih el al. 1993 [7] Sibai el al. 1995 [8] 
(, = 254) (n = 28) (n = 49) 
Gestational age on admission (weeks) 
Platelets < 100 x Iff*/I before admission 
HELLP before admission 
Eclampsia before admission 
Fetal exclusion criteria 
Prolongation of pregnancy (days) 
Maternal mortality 
Gestational age at delivery (weeks) 
Birthweight (g) 
Below 1(1 ~h percentile 
Perinatal mortality (%) 
Fetal deaths 
Neonatal deaths 
28.9 (21 31) 29,2 (24 32) 30.7 (28 32) 
95 (37.4%) 0 0 
85 (33.5%) 0 0 
12 (4.7%) 0 0 
+ + 
16.2 (0 62) 9,5 (2 26) 15.4 (4 36) 
0 0 0 
31.2 + 2.6 30.6 + 4.7 32.9 + 1.5 
1160 + 390 1480 + 450 1622 + 360 
149 (58.7%) '? 15 (30. I%) 
20.5 7.1 0 
31 0 0 
21 2 0 
Values are mean _+ S.D. (range), or numbers (percentages), as appropriate. 
The rise in protein excretion observed in the majority 
of the pre-eclamptic patients during temporizing treat- 
ment may be due to the plasma volume expansion, 
which is known to magnify proteinuria in patients with 
the nephrotic syndrome [25]. 
As shown in Table 5, a gain in pregnancy of 1 week 
appears to improve perinatal outcome considerably in 
pregnancies with a gestational age below 32 weeks, 
which agrees with previous studies [26,27]. However, 
assessment of the perinatal results of prolongation of 
pregnancy in our observational study is hampered by 
the absence of an appropriate control group, and com- 
parison with the perinatal results of expectant manage- 
ment in pre-eclamptic patients reported in the literature 
is difficult because gestational age on admission is often 
not comparable [4,15 17,19,20,28]. In addition, in 
many reports patients are excluded for various reasons, 
including fetal growth retardation and fetal distress 
[4,7,8,15 19]. Finally, because of recent advances in 
perinatal care, results obtained in recent years cannot 
be compared with those of earlier studies. Two studies 
[7,8] on expectant management in pre-eclamptic pa- 
tients with a mean gestational age on admission that is 
comparable with our study are summarized in Table 6. 
Ol/th et al. [7] reported a perinatal mortality of only 
7.1% in a retrospective analysis of 28 selected patients 
with severe pre-eclampsia n whom pregnancy was pro- 
longed by 9.5 days. In that study patients were treated 
with nifedipine and methyldopa nd were only selected 
for conservative treatment if hypertension could be 
satisfactorily controlled. Only patients without an un- 
specified maternal or fetal indication for immediate 
delivery were included. Sibai et al. [8] reported a ran- 
domized trial of aggressive (n=46)  vs. expectant 
07 = 49) management in pre-eclamptic patients between 
28 and 32 weeks gestation. Expectant management was 
begun after a stable maternal condition was obtained 
during a 24-h observation period using magnesium 
sulfate, hydralazine or nifedipine. In that study no 
perinatal mortality occurred in both groups, but pa- 
tients with fetal growth retardation and fetal distress 
were excluded. In the study by Sibai et al. [8], as well as 
in the study of Olfih et al. [7], corticosteroids to acceler- 
ate fetal lung maturation were used, which may be an 
important advantage of prolongation of pregnancy for 
at least 48 h [29,30]. During the study period corticos- 
teroids were not used in patients with pre-eclampsia n
our center. Our reluctance to administer corticosteroids 
to hypertensive patients was based on the results of the 
first randomized trial of antenatal corticosteroid ther- 
apy [31]. That trial included 90 pre-eclamptic women, 
and 12 fetal deaths were observed in 47 treated patients 
compared with three fetal deaths among 43 non-treated 
patients. Later observational studies, although small, 
have titiled to confirm an excess risk of fetal death 
associated with the use of antenatal corticosteroids in
hypertensive patients [30] and because of convincing 
evidence of its efficacy in the prevention of the neonatal 
respiratory distress syndrome, antenatal corticosteroid 
therapy was introduced in tile management of pre- 
eclamptic patients in our department in 1994. The 
perinatal mortality of 20.5% in our patients compares 
favorably with that of 62% in the 50 patients reported 
by Moodley et al. [18], in which study patients with 
impending or evident eclampsia were excluded. Also m 
this study corticosteroids were used. The study of 
Moodley et al. [18] is_omitted from Table 6, because of 
too many unreported ata. 
Our study confirms findings of earlier studies that 
permatal outcome in patients with an onset of pre- 
eclampsia before 26 weeks is generally poor [4,15,18,28] 
and cannot be markedly improved by prolongation of 
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pregnancy ,  The  h igh  inc idence o f  fetal  g rowth  re tarda-  
t ion  in our  s tudy  is cons is tent  w i th  ear l ier  repor ts  
[19,32,33] and  suggests  that  the fe ta l -p lacenta l  impact  
o f  severe pre -ec lamps ia  has  preceded over t  cl inical  dis- 
ease by a cons iderab le  per iod  o f  t ime. 
In conc lus ion ,  our  exper ience  obta ined  in a large 
number  o f  pat ients  w i th  severe ear ly -onset  p re -ec lamp-  
sia shows  that  expectant  management  wi th  p lasma vol-  
ume expans ion  and  pharmaco log ic  vasod i la ta t ion  
under  invas ive  mon i to r ing  o f  the materna l  c i rcu la t ion  
and  wi th  carefu l  surve i l lance  o f  materna l  and  fetal  
cond i t ion  may de lay  del ivery and  does  not  appear  to be 
assoc ia ted  w i th  an  increased  r isk o f  materna l  morb id i ty  
and  mor ta l i ty .  Such t reatment  shou ld  on ly  be pract i ced  
in ter t ia ry  care  centers  wi th  adequate  faci l it ies for  
mother  and  in fant .  Cont ro l led  studies  are needed to 
fu r ther  def ine the va lue  o f  tempor i z ing  hemodynamic  
t reatment  in pat ients  w i th  severe ear ly  onset  pre-  
ec lamps ia .  
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